Literature DB >> 23065574

ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder.

Jinghe Li1, Zhu-Lin Yang, Xuebao Ren, Qiong Zou, Yuan Yuan, Lufeng Liang, Meigui Chen, Senlin Chen.   

Abstract

Although the incidence of gallbladder cancers is low, they are highly aggressive tumors. Squamous cell/adenosquamous carcinoma (SC/ASC) is a rare subtype of gallbladder cancer. The clinical characteristics of SC/ASC have not been well documented, and no prognosis marker has been identified. In this study, we examined integrin-linked kinase (ILK) and peroxiredoxin-1 (PRDX1) expression in 46 SC/ASCs and 80 adenocarcinomas (ACs) by using immunohistochemistry and analyzed their correlations with clinicopathological characteristics. We demonstrated that positive ILK and PRDX1 expressions were significantly associated with large tumor size, high TNM stage, lymph node metastasis, and invasion of SC/ASC and AC. Univariate Kaplan-Meier analysis showed that positive ILK and PRDX1 expressions were closely associated with decreased overall survival in both SC/ASC (p < 0.001 and p = 0.005, respectively) and AC (p < 0.001) patients. Multivariate Cox regression analysis showed that positive ILK and PRDX1 expressions were an independent poor prognostic predictor in both SC/ASC and AC patients. We also revealed a similar significance of differentiation, tumor size, TNM stage, lymph node metastasis, invasion, and surgical curability with survival in SC/ASC and AC patients. Our study suggested that positive ILK and PRDX1 expressions are closely related to the progression and poor prognosis of gallbladder cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23065574     DOI: 10.1007/s13277-012-0557-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

1.  Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas.

Authors:  Juan C Roa; Oscar Tapia; Asli Cakir; Olca Basturk; Nevra Dursun; Deniz Akdemir; Burcu Saka; Hector Losada; Pelin Bagci; N Volkan Adsay
Journal:  Mod Pathol       Date:  2011-04-29       Impact factor: 7.842

2.  Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival.

Authors:  H Sawai; Y Okada; H Funahashi; Y Matsuo; H Takahashi; H Takeyama; T Manabe
Journal:  Oncogene       Date:  2006-01-16       Impact factor: 9.867

3.  Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma.

Authors:  Kwang-Hoe Chung; Dong Hyeon Lee; Youkyong Kim; Tae-Heon Kim; Jin Hyong Huh; Sang-Geun Chung; Sunyoung Lee; Chan Lee; Jung Jae Ko; Hee Jung An
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

4.  Expression of integrin-linked kinase is not a useful prognostic marker in resected hepatocellular cancer.

Authors:  Pongphob Intaraprasong; Kiran Assi; David A Owen; David G Huntsman; Stephen W Chung; Charles H Scudamore; Eric M Yoshida; Baljinder Salh
Journal:  Anticancer Res       Date:  2007 Nov-Dec       Impact factor: 2.480

5.  Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target.

Authors:  Joo-Heon Kim; Paul N Bogner; Sun-Hee Baek; Nithya Ramnath; Ping Liang; Hak-Ryul Kim; Chris Andrews; Young-Mee Park
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

6.  Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer.

Authors:  Changyi Quan; Eun-Jong Cha; Hyung-Lae Lee; Kwang Hee Han; Keon Myung Lee; Wun-Jae Kim
Journal:  J Urol       Date:  2006-04       Impact factor: 7.450

Review 7.  Are peroxiredoxins tumor suppressors?

Authors:  Carola Anke Neumann; Quan Fang
Journal:  Curr Opin Pharmacol       Date:  2007-07-05       Impact factor: 5.547

Review 8.  Integrin-linked kinase 1: role in hormonal cancer progression.

Authors:  Valerie Cortez; Binoj C Nair; Dimple Chakravarty; Ratna K Vadlamudi
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01

9.  Adenosquamous carcinoma of the gallbladder: a clinicopathological, immunohistochemical and flow-cytometric study of twenty cases.

Authors:  K Nishihara; E Nagai; Y Izumi; K Yamaguchi; M Tsuneyoshi
Journal:  Jpn J Cancer Res       Date:  1994-04
View more
  10 in total

1.  Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer.

Authors:  Yu-Lin Sun; Jian-Qiang Cai; Fang Liu; Xin-Yu Bi; Lan-Ping Zhou; Xiao-Hang Zhao
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

2.  Comparative Outcomes of Adenosquamous Carcinoma of the Gallbladder: an Analysis of the National Cancer Database.

Authors:  Gilbert Murimwa; Caitlin Hester; John C Mansour; Patricio M Polanco; Matthew R Porembka; Sam C Wang; Herbert J Zeh; Adam C Yopp
Journal:  J Gastrointest Surg       Date:  2020-07-23       Impact factor: 3.452

3.  Overexpression of integrin-linked kinase (ILK) promotes glioma cell invasion and migration and down-regulates E-cadherin via the NF-κB pathway.

Authors:  Feng Liang; Shuqin Zhang; Bing Wang; Jianwu Qiu; Yunjie Wang
Journal:  J Mol Histol       Date:  2013-09-13       Impact factor: 2.611

4.  Overexpression of Prdx1 in hilar cholangiocarcinoma: a predictor for recurrence and prognosis.

Authors:  Jie Zhou; Weiwen Shen; Xiaojing He; Jing Qian; Shiyuan Liu; Guanzhen Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

5.  Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma.

Authors:  Qi-Kai Sun; Jian-Yu Zhu; Wei Wang; Yang Lv; Hang-Cheng Zhou; Ji-Hai Yu; Ge-Liang Xu; Jin-Liang Ma; Wen Zhong; Wei-Dong Jia
Journal:  Med Oncol       Date:  2013-12-03       Impact factor: 3.064

6.  Integrin-linked kinase overexpression promotes epithelial-mesenchymal transition via nuclear factor-κB signaling in colorectal cancer cells.

Authors:  Hong Shen; Jun-Li Ma; Yan Zhang; Gan-Lu Deng; Yan-Ling Qu; Xiao-Ling Wu; Jing-Xuan He; Sai Zhang; Shan Zeng
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

7.  Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study.

Authors:  Lianghe Jiao; Jing Wei; Jun Ye; Chuanmeng Zhang
Journal:  Dis Markers       Date:  2021-03-03       Impact factor: 3.434

8.  Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma.

Authors:  Pengfei Ren; Hua Ye; Liping Dai; Mei Liu; Xinxin Liu; Yurong Chai; Qing Shao; Yang Li; Ningjing Lei; Bo Peng; Wu Yao; Jianying Zhang
Journal:  Oncol Rep       Date:  2013-09-04       Impact factor: 3.906

9.  Silencing of ILK attenuates the abnormal proliferation and migration of human Tenon's capsule fibroblasts induced by TGF-β2.

Authors:  Yao Xing; Lijun Cui; Qianyan Kang
Journal:  Int J Mol Med       Date:  2016-06-16       Impact factor: 4.101

Review 10.  Peroxiredoxin 1 - an antioxidant enzyme in cancer.

Authors:  Chenbo Ding; Xiaobo Fan; Guoqiu Wu
Journal:  J Cell Mol Med       Date:  2016-09-21       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.